Dynamics, Pharmacokinetics, and Dosimetry of First-in-Human [ 68 Ga]Ga-OncoACP3-DOTA PET in Patients with Prostate Cancer
Journal of Nuclear Medicine · 2026-07 · 67 (7) · 1079-1085
DOI: 10.2967/jnumed.125.271933 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 30.04.2026. Verfasst von Julia Brosch-Lenz und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Münster, Münster, Germany. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Gallium Radioisotopes, Heterocyclic Compounds, 1-Ring, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
This study aimed to investigate the dynamics, pharmacokinetic characteristics, and radiation dosimetry of [68Ga]Ga-OncoACP3-DOTA, a novel prostatic acid phosphatase (ACP3)-targeted radioligand, in patients with metastatic castration-resistant prostate cancer. Methods: Seven patients with metastatic castration-resistant prostate cancer had dynamic or multiple-time-point PET/CT scans after intravenous injection of [68Ga]Ga-OncoACP3-DOTA available. Five patients had early dynamic scans over the thorax, and 6 had dynamic whole-body PET scans during the first hour after injection. Five patients underwent an additional late-time-point whole-body PET scan (median, 3.2 h postinjection). SUVs for volumes of interest were determined for normal organs and metastases, and uptake dynamics and tumor-to-background ratios were calculated. Pharmacokinetic modeling was performed for multiple compartment models and evaluated in accordance with the Akaike information criterion. Dosimetry calculations were performed using MIRDfit and MIRDcalc, with time-integrated activity coefficients scaled to the International Commission on Radiological Protection 133 Adult Male Reference Phantom. Results: [68Ga]Ga-OncoACP3-DOTA displayed declining uptake in most organs, except for organs involved in excretion, and stable uptake was observed only in the prostate. Dual renal and hepatobiliary excretion was noted. Declining blood kinetics were well-fitted by a triexponential function. Metastases showed an increase in uptake from early to late time points, with intensely increasing tumor-to-background ratios. Pharmacokinetic modeling indicated that a 2-tissue compartment model with irreversible binding was most appropriate for describing metastatic uptake. Bone and lymph node metastases exhibited significant differences in K 1 and K i values. The mean effective dose was 0.0192 mSv/MBq, resulting in an effective dose of 3.50 mSv for a standard injection of 2.5 MBq/kg. The highest absorbed doses were observed in bone marrow (0.0913 mGy/MBq), kidneys (0.0657 mGy/MBq), and liver (0.0563 mGy/MBq), whereas salivary glands showed a negligible absorbed dose (0.0135 mGy/MBq). Conclusion: [68Ga]Ga-OncoACP3-DOTA demonstrated favorable pharmacokinetics with increasing tumor uptake and tumor-to-background ratios at later time points, suggesting potential benefits for delayed imaging, especially with high-sensitive PET systems or radiolabeling with isotopes with longer half-lives. The dosimetry profile was favorable, with a lower effective dose compared with many prostate-specific membrane antigen-targeted radiopharmaceuticals and negligible salivary gland uptake, potentially reducing side effects during radiopharmaceutical therapy. Future studies are warranted to evaluate its clinical value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, University Hospital Münster, Münster, Germany.
- European Institute for Molecular Imaging, University of Münster, Münster, Germany.
- Philochem AG, Otelfingen, Switzerland.
- Clinic for Radiology, University Hospital Münster, Münster, Germany.
- Department of Urology, University Hospital Münster, Münster, Germany.
- Philogen Spa, Siena, Italy; and.
Zitieren
APA
Brosch-Lenz, J., Büther, F., Oehler, S., Ciamarone, A., Georgiev, T., Schindler, P., Landau, F., Breyholz, H. J., Ventura, D., Rust, M., Schlack, K., Bögemann, M., Puca, E., Mock, J., Cazzamalli, S., Neri, D., Rahbar, K., Schrader, A. J., Schäfers, M., …, & Backhaus, P. (2026). Dynamics, Pharmacokinetics, and Dosimetry of First-in-Human [ 68 Ga]Ga-OncoACP3-DOTA PET in Patients with Prostate Cancer. Journal of Nuclear Medicine, 67(7), 1079-1085. https://doi.org/10.2967/jnumed.125.271933
Vancouver
Brosch-Lenz J, Büther F, Oehler S, Ciamarone A, Georgiev T, Schindler P, et al. Dynamics, Pharmacokinetics, and Dosimetry of First-in-Human [ 68 Ga]Ga-OncoACP3-DOTA PET in Patients with Prostate Cancer. Journal of Nuclear Medicine. 2026;67(7):1079-1085. doi:10.2967/jnumed.125.271933
BibTeX
@article{BroschLenz2026,
author = {Brosch-Lenz, Julia and Büther, Florian and Oehler, Sebastian and Ciamarone, Andrea and Georgiev, Tony and Schindler, Philipp and Landau, Felicitas and Breyholz, Hans-Jörg and Ventura, David and Rust, Martin and Schlack, Katrin and Bögemann, Martin and Puca, Emanuele and Mock, Jacqueline and Cazzamalli, Samuele and Neri, Dario and Rahbar, Kambiz and Schrader, Andres Jan and Schäfers, Michael and Seifert, Konstantin Egon and Backhaus, Philipp},
title = {Dynamics, Pharmacokinetics, and Dosimetry of First-in-Human [ 68 Ga]Ga-OncoACP3-DOTA PET in Patients with Prostate Cancer},
journal = {Journal of Nuclear Medicine},
year = {2026},
volume = {67},
number = {7},
pages = {1079--1085},
doi = {10.2967/jnumed.125.271933}
}
EUVIMED